LPC
BNTC icon

Lion Point Capital’s Benitec Biopharma BNTC Stock Holding History

Lion Point Capital’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$660K Hold
62,000
– – 3.95% 9
2025
Q4 		$835K Hold
62,000
– – 4.32% 6
2025
Q3 		$870K Hold
62,000
– – 4.94% 9
2025
Q2 		$725K Hold
62,000
– – 4.93% 10
2025
Q1 		$807K Hold
62,000
– – 5.15% 7
2024
Q4 		$783K Buy
62,000
+23,000
+59% +$248K 4.1% 10
2024
Q3 		$358K Buy
+39,000
New +$349K 0.8% 19

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Lion Point Capital's BNTC Position: Q1 2026 in Review

Lion Point Capital held its Benitec Biopharma (BNTC) position steady in Q1 2026 at 62,000 shares worth $660K. The position accounts for 3.95% of the portfolio, ranked #9.

Lion Point Capital first reported a position in BNTC in Q3 2024 and has held it in 7 quarters since. The position peaked at $870K in Q3 2025. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

  • Lion Point Capital held 62,000 shares of Benitec Biopharma worth $660K as of Q1 2026.
  • Lion Point Capital left its Benitec Biopharma share count unchanged in Q1 2026.
  • Benitec Biopharma made up 3.95% of Lion Point Capital's portfolio in Q1 2026, its #9 holding.
  • Lion Point Capital first reported a position in Benitec Biopharma in Q3 2024 and has held it in 7 quarters since.
  • Lion Point Capital's Benitec Biopharma position peaked at $870K in Q3 2025.
  • 88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on Lion Point Capital's 13F filing for Q1 2026, filed 15 May 2026.